ProKidney Corp (NASDAQ:PROK): -448.15% Off High, Can It Comeback?

In last trading session, ProKidney Corp (NASDAQ:PROK) saw 0.59 million shares changing hands with its beta currently measuring 1.53. Company’s recent per share price level of $0.81 trading at -$0.04 or -5.07% at ring of the bell on the day assigns it a market valuation of $236.09M. That closing price of PROK’s stock is at a discount of -448.15% from its 52-week high price of $4.44 and is indicating a premium of 43.21% from its 52-week low price of $0.46. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.65 million shares which gives us an average trading volume of 811.84K if we extend that period to 3-months.

For ProKidney Corp (PROK), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.20. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.

ProKidney Corp (NASDAQ:PROK) trade information

Upright in the red during last session for losing -5.07%, in the last five days PROK remained trading in the green while hitting it’s week-highest on Friday, 05/16/25 when the stock touched $0.81 price level, adding 9.99% to its value on the day. ProKidney Corp’s shares saw a change of -52.27% in year-to-date performance and have moved 11.81% in past 5-day. ProKidney Corp (NASDAQ:PROK) showed a performance of 1.34% in past 30-days. Number of shares sold short was 15.64 million shares which calculate 11.84 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 5 to the stock, which implies a rise of 83.8% to its current value. Analysts have been projecting 3 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -270.37% in reaching the projected high whereas dropping to the targeted low would mean a loss of -270.37% for stock’s current value.

ProKidney Corp (PROK) estimates and forecasts

In 2025, company’s earnings growth rate is likely to be around 6.93% while estimates for its earnings growth in next 5 years are of -2.31%.

ProKidney Corp (NASDAQ:PROK)’s Major holders

Insiders are in possession of 30.05% of company’s total shares while institution are holding 41.84 percent of that, with stock having share float percentage of 59.81%. Investors also watch the number of corporate investors in a company very closely, which is 41.84% institutions for ProKidney Corp that are currently holding shares of the company. MORGAN STANLEY is the top institutional holder at PROK for having 14.45 million shares of worth $35.54 million. And as of 2024-06-30, it was holding 19.034 of the company’s outstanding shares.

The second largest institutional holder is SUVRETTA CAPITAL MANAGEMENT, LLC, which was holding about 9.34 million shares on 2024-06-30. The number of shares represents firm’s hold over 12.306 of outstanding shares, having a total worth of $22.98 million.

On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and MORGAN STANLEY INSTITUTIONAL FUND INC-GROWTH PORTFOLIO are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 2.97 shares of worth $2.39 million or 2.29% of the total outstanding shares. The later fund manager was in possession of 2.92 shares on Dec 31, 2024 , making its stake of worth around $2.36 million in the company or a holder of 2.26% of company’s stock.

Marketing Sentinel
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.